September 10, 2025European Journal of CancerOpen Access

NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma

View Full Paper

Ask AI

Bookmark

Neoadjuvant atezolizumab and tiragolumab resulted in a promising 12-month event-free survival of 72.0%.
Among patients evaluated, major pathologic responses were observed in 47.1% of cases, indicating substantial treatment efficacy.
The study involved four cycles of neoadjuvant therapy, followed by surgical intervention, showcasing a comprehensive treatment approach.
A favorable safety profile was noted, with only 5.9% of patients experiencing severe treatment-related adverse events.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase II trial demonstrates significant improvements in event-free survival and safety for patients with advanced melanoma, suggesting the need for personalized treatment strategies.

Cite This Study

Hieken et al. (2025) studied this question.

synapsesocial.com/papers/68c241acb210217d647a047a https://doi.org/10.1016/j.ejca.2025.115688

View Full Paper

Ask AI

Bookmark

Implication

Phase II trial demonstrates significant improvements in event-free survival and safety for patients with advanced melanoma, suggesting the need for personalized treatment strategies.

NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma

Key Points

Discussion

Implication

Cite This Study

NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading